What the FDA labels say about taking them together
Erlotinib and pantoprazole
Pantoprazole's FDA label of May 18, 2026 names erlotinib in its drug interactions section; erlotinib's label does not name pantoprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The pantoprazole label: “Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.”
Check it at the source: the erlotinib FDA label on DailyMed (effective June 10, 2024, Alembic Pharmaceuticals Limited); the pantoprazole FDA label on DailyMed (effective May 18, 2026, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the erlotinib label say about pantoprazole?
Erlotinib's label does not name pantoprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Erlotinib label, drug interactionsDrugs the Increase Gastric pH Co-administration of erlotinib with proton pump inhibitors (e.g., omeprazole) and H-2 receptor antagonists (e.g., ranitidine) decreased erlotinib exposure [see Clinical Pharmacology (12.3)].
Erlotinib label, drug interactionsFor proton pump inhibitors, avoid concomitant use if possible.
Source: FDA drug label (ERLOTINIB HYDROCHLORIDE), Alembic Pharmaceuticals Limited, effective June 10, 2024 (SPL set ab6f3cb3-34a8-4492-a5d7-fb6b055a2d6b), via openFDA; the full label on DailyMed
What does the pantoprazole label say about erlotinib?
Pantoprazole label, drug interactionsClinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Mycophenolate mofetil (MMF): Co-administration of pantoprazole sodium in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH …
Pantoprazole Sodium label (Hikma Pharmaceuticals USA Inc., July 19, 2023), drug interactionsDrugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, n ilotinib, mycophenoloate mofetil, ketoconazole/itraconazole) C linical Impact:
Source: FDA drug label (Pantoprazole Sodium, NDA209463), Hikma Pharmaceuticals USA Inc., effective July 19, 2023 (SPL set 1e102c44-232b-4aaf-b457-2a740c47193a), via openFDA
Source: FDA drug label (Protonix Delayed-Release), Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective May 18, 2026 (SPL set 08098cb2-c048-4640-f387-6beec4a38936), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Erlotinib | Pantoprazole | |
|---|---|---|
| Labeled for | Lung cancer | Acid reflux and ulcers |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.0358 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once